NGLY1 and melanoma: Notably, the anti-melanoma activity of IFNβ and IL-29 has been demonstrated in previous studies.35–37 These findings definitively illustrate that NGLY1 suppression-induced cytokine surges and relevant cellular responses contribute to anticancer effects.